LT3001 + dabigatran

LT3001 + dabigatran is an experimental combination therapy for **acute ischemic stroke**. LT3001 (odatroltide) is a novel small synthetic peptide developed to promote vascular recanalization in ischemic stroke by enhancing endogenous fibrinolysis, limiting oxidative stress, and protecting brain tissue from reperfusion injury[1][2][4]. Dabigatran is an oral direct thrombin inhibitor anticoagulant, widely used for stroke prevention in atrial fibrillation and prevention or treatment of venous thromboembolism[5]. The combination is under investigation to determine if LT3001 can be safely administered with anticoagulants like dabigatran, aiming to improve stroke outcomes without increasing bleeding risk[1]. LT3001 is delivered intravenously, while dabigatran is administered orally[1][5]. Developers are testing both the safety and efficacy of this combination for patients with acute ischemic stroke, including those who may also receive thrombectomy or other antiplatelet/anticoagulant therapies[1][2].

Other names

odatroltidedabigatran etexilate